Inhibitors of bruton's tyrosine kinase

Abstract

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

1 .- 21 . (canceled) 
     
     
         22 . A method for treating a B-cell proliferative disorder in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) and the second agent is cytarabine, wherein the irreversible inhibitor is a compound having the structure of Formula (A): 
       
         
           
           
               
               
           
         
         wherein: 
         A is N; 
         R 1  is phenyl-O-phenyl or phenyl-S-phenyl; 
         R 2  and R 3  are independently H; 
         R 4  is L 3 -X-L 4 -G, wherein,
 L 3  is optional, and when present is an optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, optionally substituted or unsubstituted alkynyl; 
 X is optional, and when present is O, —C(═O), S, —S(═O), —S(═O) 2 , —NH, —NR 9 , —NHC(O), —C(O)NH, —NR 9 C(O), —C(O)NR 9 , —S(═O) 2 NH, —NHS(═O) 2 , —S(═O) 2 NR 9 —, —NR 9 S(═O) 2 , —OC(O)NH—, —NHC(O)O—, —OC(O)NR 9 —, —NR 9 C(O)O—, —CH═NO—, —ON═CH—, —NR 10 C(O)NR 10 —, heteroaryl, aryl, —NR 10 C(═NR 11 )NR 10 —, —NR 10 C(═NR 11 )—, —C(═NR 11 )NR 10 —, —OC(═NR 11 )—, or —C(═NR 11 )O—; 
 L 4  is optional, and when present is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle; 
 or L 3 , X and L 4  taken together form a nitrogen containing heterocyclic ring; 
 G is 
 
       
       
         
           
           
               
               
           
         
         
           
             wherein, 
             R 6 , R 7  and R 8  are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; 
           
         
         each R 9  is independently selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl; 
         each R 10  is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or 
         two R 10  groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or 
         R 9  and R 10  can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; and 
         each R 11  is independently selected from H, —S(═O) 2 R 8 , —S(═O) 2 NH 2 , —C(O)R 8 , —CN, —NO 2 , heteroaryl, or heteroalkyl; or pharmaceutically acceptable salts thereof. 
       
     
     
         23 . The method of  claim 22 , wherein the B-cell proliferative disorder is a leukemia. 
     
     
         24 . The method of  claim 22 , wherein the B-cell proliferative disorder is acute myelogenous leukemia. 
     
     
         25 . The method of  claim 22 , wherein the irreversible inhibitor of Btk and the second agent are administered simultaneously. 
     
     
         26 . The method of  claim 22 , wherein the irreversible inhibitor of Btk and the second agent are administered sequentially. 
     
     
         27 . The method of  claim 22 , wherein the irreversible inhibitor of Btk is administered orally. 
     
     
         28 . The method of  claim 22  wherein L 3 , X and L 4  taken together form a nitrogen containing heterocyclic ring. 
     
     
         29 . The method of  claim 22  wherein G is 
       
         
           
           
               
               
           
         
       
     
     
         30 . The method of  claim 22  wherein R 6 , R 7 , and R 8  are each independently H. 
     
     
         31 . The method of  claim 22  wherein the first agent has the structure 
       
         
           
           
               
               
           
         
          or a pharmaceutically acceptable salt thereof. 
       
     
     
         32 . A method for treating acute myelogenous leukemia in a subject in need thereof comprising administering to the subject two or more agents, wherein the first agent has the structure 
       
         
           
           
               
               
           
         
          and the second agent is cytarabine.